Rivus Pharmaceuticals
Small-molecule therapeutics targeting mitochondrial biology for obesity treatment
- Sector
- Biotech
- Headquarters
- CHARLOTTESVILLE, VA
- Founded
- 2019
- Latest Form D
- $57M, Jan 2025
- Total capital
- $223M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $223M
- 4 Form D · last Jan 2025
- 21 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 30 pending · first 2020
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$57M
- Private capital raisedForm D · SEC · 3rd filing$66M
- Private capital raisedForm D · SEC · 2nd filing$66M
- Private capital raisedForm D · SEC · 1st filing$34.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Allen CunninghamExecutive Officer, DirectorNamed in SEC Form D filings
- Derek DiRoccoDirectorNamed in SEC Form D filings
- Erin LavelleDirectorNamed in SEC Form D filings
- Francesco De RubertisDirectorNamed in SEC Form D filings
- Ian SmithDirectorNamed in SEC Form D filings
- Jayson DallasExecutive Officer, DirectorNamed in SEC Form D filings
Show all 12 people
- Nancy HargreavesExecutive OfficerNamed in SEC Form D filings
- Patrick EnrightDirectorNamed in SEC Form D filings
- Rick WinninghamDirectorNamed in SEC Form D filings
- Robert SchottExecutive OfficerNamed in SEC Form D filings
- Shaharyar KhanExecutive Officer, DirectorNamed in SEC Form D filings
- Tom O'NeilExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 31- PendingCrystalline Forms Of 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-1H-IMIDAZOLEUSPTOApplication 19211720
- PendingNovel Phenyl DerivativesUSPTOApplication 19084367
- PendingMethods Of Treating Mitochondria-related DisordersUSPTOApplication 18562560
Show all 31 patent records
- Crystalline Forms Of 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-1H-IMIDAZOLEApr 9, 2026 · Application 19211720Pending
- Novel Phenyl DerivativesJul 3, 2025 · Application 19084367Pending
- Methods Of Treating Mitochondria-related DisordersJun 5, 2025 · Application 18562560Pending
- Methods Of Weight Loss In A Subject With Elevated HBA1CMay 1, 2025 · Application 18835578Pending
- Methods Of Weight Loss And Preserving Skeletal Muscle MassMay 1, 2025 · Application 18835559Pending
- Novel Phenyl DerivativesFeb 17, 2022 · Application 17513235Pending
- Novel Phenyl DerivativesAug 5, 2021 · Application 17231168Pending
- Novel Phenyl DerivativesDec 24, 2020 · Application 17010547Pending
- Novel Phenyl DerivativesApr 14, 2020 · US 10,618,875Granted
- Methods Of Treating Non-alcoholic Fatty Liver DiseaseApplication 63382426Pending
- Methods Of Weight Loss And Preserving Skeletal Muscle MassApplication 63382456Pending
- Methods Of Treating Mitochondria-related DisordersApplication PCTUS2022029992Pending
- Methods Of Treating Mitochondria-related DisordersApplication 63307515Pending
- Methods Of Weight Loss And Preserving Skeletal Muscle MassApplication 63307506Pending
- METHODS OF WEIGHT LOSS IN A SUBJECT WITH ELEVATED HbA1cApplication 63307470Pending
- Methods Of Treating Mitochondria-related DisordersApplication 63222841Pending
- Methods of Treating Cardiovascular DiseasesApplication 63191321Pending
- Novel Phenyl DerivativesApplication 16789659Pending
- Deuterium Enriched Phenyl Derivatives For Treating Mitochondriarelated Disorders Or ConditionsApplication 19131038Pending
- Crystalline Forms Of 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-1H-IMIDAZOLEApplication 19131044Pending
- Novel Phenyl DerivativesApplication PCTUS2018012491Pending
- Novel Phenyl DerivativesApplication 62581355Pending
- Novel Phenyl DerivativesApplication 62443244Pending
- Novel Phenyl DerivativesApplication 18793069Pending
- Crystalline Forms Of 5-[(2,4-DINITROPHENOXY)METHYL]-1- METHYL-2-NITRO-1H-IMIDAZOLEApplication 63650681Pending
- Novel Deuterium Enriched Phenyl DerivativesApplication PCTUS2023080524Pending
- Crystalline Forms Of 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-1H-IMIDAZOLEApplication PCTUS2023080519Pending
- Methods Of Weight Loss And Preserving Skeletal Muscle MassApplication PCTUS2023062077Pending
- Methods Of Weight Loss In A Subject With Elevated HBA1CApplication PCTUS2023062065Pending
- Novel Deuterium Enriched Phenyl DerivativesApplication 63384542Pending
- Crystalline Froms Of 5-[(2,4-DINITROPHENOXY)METHYL]-1-METHYL-2-NITRO-1H-IMIDAZOLEApplication 63384478Pending
Related companies, and why
- Capstan TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Apnimed, Inc.Similar federal contract value in Biotech · null in contracts
- Seaport TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Cyclerion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Endeavor BioMedicinesSimilar federal contract value in Biotech · null in contracts
- AbsciSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .